Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · see citing works

Statistical significance for genomewide studies

Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692 · see citing works

Genomic analyses identify molecular subtypes of pancreatic cancer

Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · see citing works

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works

OncoKB: A Precision Oncology Knowledge Base

Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R. D., Soumerai, T. E., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,735 · see citing works

Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer

Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302 · see citing works

Topoisomerase I inhibitors: camptothecins and beyond

Pommier, Y. G. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1977 · Cited by 2,294 · see citing works

Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes

McGuigan, A. J., Kelly, P. J., Turkington, R. C., Jones, C. A., Coleman, H. G., & McCain, R. S. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i43.4846 · Cited by 1,933 · see citing works

Pancreatic Cancer

Park, W., Chawla, A., & O'Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,931 · see citing works

Genetics and biology of pancreatic ductal adenocarcinomaPreprint

Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. M., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,570 · see citing works

FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing

Shen, R., & Seshan, V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw520 · Cited by 1,263 · see citing works

BRCAness revisited

Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257 · see citing works

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136 · see citing works

Incidence of Cancer in 161 Families Affected by Ataxia–Telangiectasia

Swift, M., Morrell, D., Massey, R. B., & Chase, C. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112263252602 · Cited by 934 · see citing works

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657 · see citing works

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

Pishvaian, M. J., Blais, E. M., Brody, J. R., Lyons, E. E., DeArbeloa, P., Hendifar, A. E., Mikhail, S., Chung, V. M., Sahai, V., Sohal, D. P. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30074-7 · Cited by 548 · see citing works

Genetics and biology of pancreatic ductal adenocarcinoma

Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes &amp; Development · doi:10.1101/gad.275776.115 · Cited by 527 · see citing works

<i>ATM</i> Mutations in Patients with Hereditary Pancreatic Cancer

Roberts, N. J., Jiao, Y., Yu, J., Kopelovich, L., Petersen, G. M., Bondy, M. L., Gallinger, S., Schwartz, A. G., Syngal, S., Cote, M. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0194 · Cited by 491 · see citing works

ATM Mutations in Cancer: Therapeutic Implications

Choi, M. P., Kipps, T. J., & Kurzrock, R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0945 · Cited by 456 · see citing works

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., Aderka, D., Paluch–Shimon, S., Kaufman, B., Gershoni‐Baruch, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.418 · Cited by 437 · see citing works

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

O'Reilly, E. M., Lee, J. W., Zalupski, M. M., Capanu, M., Park, J., Golan, T., Tahover, E., Lowery, M. A., Chou, J. F., Sahai, V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02931 · Cited by 405 · see citing works

Tumour lineage shapes BRCA-mediated phenotypes

Jonsson, P., Bandlamudi, C., Cheng, M. L., Srinivasan, P., Chavan, S. S., Friedman, N. D., Rosen, E. Y., Richards, A. L., Bouvier, N., Selçuklu, S. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1382-1 · Cited by 404 · see citing works

Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer

Sztupinszki, Z. M., Dióssy, M., Krzystanek, M., Reiniger, L., Csabai, I., Favero, F., Birkbak, N. J., Eklund, A. C., Syed, A., & Szállási, Z. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0066-6 · Cited by 310 · see citing works

CHK2 kinase: cancer susceptibility and cancer therapy – two sides of the same coin?

Antoni, L., Sodha, N., Collins, I., & Garrett, M. D. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2251 · Cited by 287 · see citing works

Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview

Kciuk, M., Marciniak, B., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144919 · Cited by 266 · see citing works

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection

Park, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M., Balachandran, V. P., McIntyre, C. A., Dika, I. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0418 · Cited by 237 · see citing works

ATM mutations in B-cell chronic lymphocytic leukemia.

Bullrich, F., Rasio, D., Kitada, S., Starostik, P., Kipps, T. J., Keating, M., Albitar, M. X., Reed, J. C., & Croce, C. M. (1999) · PubMed · Cited by 232 · see citing works

Characterization of ATM gene mutations in 66 ataxia telangiectasia families

Sandoval, N. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.1.69 · Cited by 226 · see citing works

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

Lowery, M. A., Wong, W., Jordan, E. J., Lee, J. W., Kemel, Y., Vijai, J., Mandelker, D., Zehir, A., Capanu, M., Salo-Mullen, E., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy024 · Cited by 224 · see citing works

Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype

Lowery, M. A., Jordan, E., Baştürk, O., Ptashkin, R. N., Zehir, A., Berger, M. F., Leach, T., Herbst, B. T., Askan, G., Maynard, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0899 · Cited by 212 · see citing works

Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

Latenstein, A. E. J., van der Geest, L. G., Bonsing, B. A., Koerkamp, B. G., Mohammad, N. H., de Hingh, I. H. J. T., de Meijer, V. E., Molenaar, I. Q., van Santvoort, H. C., van Tienhoven, G., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.002 · Cited by 187 · see citing works

Pathogenesis of Colloid (Pure Mucinous) Carcinoma of Exocrine Organs

Adsay, V. N., Merati, K., Nassar, H., Shia, J., Sarkar, F. H., Pierson, C. R., Cheng, J. D., Visscher, D. W., Hruban, R. H., & Klimstra, D. S. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200305000-00002 · Cited by 178 · see citing works

Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma

Golan, T., O'Kane, G. M., Denroche, R. E., Raitses‐Gurevich, M., Grant, R. C., Holter, S., Wang, Y., Zhang, A. X. W., Jang, G. H., Stossel, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.220 · Cited by 155 · see citing works

The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?

Ngoi, N. Y. L., & Tan, D. S. P. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100144 · Cited by 140 · see citing works

Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.

Starostik, P., Manshouri, T., O'Brien, S. M., Freireich, E. J., Kantarjian, H., Haidar, M. A., Lerner, S. A., Keating, M. J., & Albitar, M. X. (1998) · PubMed · Cited by 136 · see citing works

Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study

Golan, T., Raitses‐Gurevich, M., Kelley, R. K., Bocobo, A. G., Borgida, A., Shroff, R. T., Holter, S., Gallinger, S., Ahn, D. H., Aderka, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0415 · Cited by 128 · see citing works

The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers

Weigelt, B., Bi, R., Kumar, R., Blecua, P., Mandelker, D. L., Geyer, F. C., Pareja, F., James, P. A., kConFab Investigators, Couch, F. J., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy028 · Cited by 128 · see citing works

Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program

Pishvaian, M. J., Blais, E. M., Brody, J. R., Rahib, L., Lyons, E. E., Arbeloa, P., Hendifar, A. E., Mikhail, S., Chung, V. M., Sohal, D. P. S., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00115 · Cited by 103 · see citing works

Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study

Wang, H., Liu, J., Xia, G., Lei, S., Huang, X., & Huang, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-64068-3 · Cited by 93 · see citing works

The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice

Stucci, L. S., Internò, V., Tucci, M., Perrone, M., Mannavola, F., Palmirotta, R., & Porta, C. (2021) · Genes · doi:10.3390/genes12050727 · Cited by 92 · see citing works

Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the <i>ATM</i> Gene

Hsu, F.-C., Roberts, N. J., Childs, E., Porter, N., Rabe, K. G., Borgida, A., Ukaegbu, C., Goggins, M. G., Hruban, R. H., Zogopoulos, G., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3701 · Cited by 91 · see citing works

BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma

Blair, A. B., Groot, V. P., Gemenetzis, G., Wei, J., Cameron, J. L., Weiss, M. J., Goggins, M., Wolfgang, C. L., Yu, J., & He, J. P. (2018) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2017.12.021 · Cited by 85 · see citing works

Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer

Chen, Y., Chen, G., Li, J., Huang, Y., Li, Y., Lin, J., Chen, L., Lu, J., Wang, Y., Wang, C., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.11895 · Cited by 85 · see citing works

ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications

Armstrong, S. A., Schultz, C. W., Azimi-Sadjadi, A., Brody, J. R., & Pishvaian, M. J. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0208 · Cited by 74 · see citing works

Resampling Procedures to Compare Two Survival Distributions in the Presence of Right-Censored Data

Heller, G., & Venkatraman, E. S. (1996) · Biometrics · doi:10.2307/2532836 · Cited by 70 · see citing works

Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy

Pitter, K. L., Casey, D. L., Lu, Y. C., Hannum, M., Zhang, Z., Song, X., Pecorari, I. L., McMillan, B., Ma, J., Samstein, R. M., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa095 · Cited by 69 · see citing works

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer

Randon, G., Fucà, G., Rossini, D., Raimondi, A., Pagani, F., Perrone, F., Tamborini, E., Busico, A., Peverelli, G., Morano, F., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39525-3 · Cited by 68 · see citing works

ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas

Bueno, R. C., Canevari, R. D. A., Villacis, R. A. R., Domingues, M. A. C., Caldeira, J. R. F., Rocha, R. M., Drigo, S. A., & Rogatto, S. R. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt421 · Cited by 65 · see citing works

FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study

Cho, I. R., Kang, H., Jo, J. H., Lee, H. S., Chung, M. J., Park, J. Y., Park, S. W., Song, S. Y., An, C., Park, M., et al. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i2.182 · Cited by 63 · see citing works

Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort

Leibowitz, B. D., Dougherty, B. V., Bell, J. S. K., Kapilivsky, J., Michuda, J., Sedgewick, A. J., Munson, W., Chandra, T. A., Dry, J. R., Beaubier, N. T., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09669-z · Cited by 56 · see citing works

Pancreas cancer and <i>BRCA</i> : A critical subset of patients with improving therapeutic outcomes

Momtaz, P., O’Connor, C. A., Chou, J. F., Capanu, M., Park, W., Bandlamudi, C., Berger, M. F., Kelsen, D. P., Suehnholz, S. P., Chakravarty, D., et al. (2021) · Cancer · doi:10.1002/cncr.33812 · Cited by 44 · see citing works

Targeting DNA damage repair pathways in pancreas cancer

Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09983-1 · Cited by 43 · see citing works

Colloid carcinoma of the pancreas: review of selected pathological and clinical aspects

Liszka, Ł., Zielińska‐Pająk, E., Pająk, J., & Gołka, D. (2008) · Pathology · doi:10.1080/00313020802436444 · Cited by 41 · see citing works

Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells

Wang, Y., Yang, L., Zhang, J., Zhou, M., Shen, L., Deng, W., Liang, L., Hu, R., Wang, Y., Yao, Y., et al. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4514 · Cited by 41 · see citing works

ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients

Marečková, A., Malčíková, J., Tom, N., Pál, K., Radová, L., Šálek, D., Janíková, A., Moulis, M., Šmardová, J., Křen, L., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1542144 · Cited by 38 · see citing works

A Genomic Instability Score in Discriminating Nonequivalent Outcomes of BRCA1/2 Mutations and in Predicting Outcomes of Ovarian Cancer Treated with Platinum-Based Chemotherapy

Zhang, S.-J., Yuan, Y., & Hao, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113169 · Cited by 37 · see citing works

Homologous repair deficiency score for identifying breast cancers with defective DNA damage response

Min, A., Kim, K., Jeong, K., Choi, S., Kim, S., Suh, K. J., Lee, K.-H., Kim, S., & Im, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-68176-y · Cited by 30 · see citing works

ATM Serine/Threonine Kinase and its Role in Pancreatic Risk

Nanda, N., & Roberts, N. J. (2020) · Genes · doi:10.3390/genes11010108 · Cited by 29 · see citing works

Current treatment landscape and emerging therapies for pancreatic cancer.

Adel, N. G. (2019) · PubMed · Cited by 28 · see citing works

Differential treatment outcomes in BRCA1/2‐, CDK12‐, and ATM‐mutated metastatic castration‐resistant prostate cancer

Kwon, D. H.-M., Chou, J., Yip, S., Reimers, M. A., Zhang, L., Wright, F., Dhawan, M. S., Borno, H. T., Desai, A., Aggarwal, R. R., et al. (2021) · Cancer · doi:10.1002/cncr.33487 · Cited by 27 · see citing works

Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants

Hutchings, D., Jiang, Z., Skaro, M. F., Weiss, M. J., Wolfgang, C. L., Makary, M. A., He, J. P., Cameron, J. L., Zheng, L., Klimstra, D. S., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0317-6 · Cited by 26 · see citing works

A novel mechanism of irinotecan targeting MDM2 and Bcl-xL

Lee, B., Min, J. A., Nashed, A., Lee, S.-O., Yoo, J. C., Chi, S., & Yi, G. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.009 · Cited by 25 · see citing works

ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer

Sun, L., Wang, R.-C., Zhang, Q., & Guo, L. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153032 · Cited by 24 · see citing works

Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations

Hannan, Z. M., Yu, S., Domchek, S. M., Mamtani, R., & Reiss, K. A. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa121 · Cited by 20 · see citing works

Diagnostic Strategy of Early Stage Pancreatic Cancer via Clinical Predictor Assessment: Clinical Indicators, Risk Factors and Imaging Findings

Sagami, R., Sato, T., Mizukami, K., Motomura, M., Okamoto, K., Fukuchi, S., Otsuka, Y., Abe, T., Ono, H., Mori, K., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020377 · Cited by 14 · see citing works

ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications

Jabbour, T. E., Misyura, M., Cowzer, D., Zimmermann, M., Rimkunas, V. M., Marra, A., Derakhshan, F. N., Selenica, P., Parilla, M., Setton, J. S., et al. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac024 · Cited by 12 · see citing works

Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer

Macklin‐Mantia, S. K., Hines, S. L., & Kasi, P. M. (2020) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-020-00148-9 · Cited by 5 · see citing works

ATM mutation carriers and family history of pancreatic cancer.

Klavanian, J., Zakalik, D., Konde, A. S., & Rangarajan, T. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1529 · Cited by 4 · see citing works

Association of germline ATM mutations and survival in pancreatic cancer

Gower, A., Gresham, G. K., Spector, K., Haladjian, N., Lee, J., Mehta, S., Osipov, A., & Hendifar, A. E. (2021) · Annals of Pancreatic Cancer · doi:10.21037/apc-20-38 · Cited by 3 · see citing works

Pancreatic cancer: Advances and challenges

Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321 · see citing works

Therapeutic developments in pancreatic cancer

Hu, Z., & O'Reilly, E. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 425 · see citing works

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Varghese, A. M., Perry, M., Chou, J. F., Nandakumar, S., Muldoon, D. M., Erakky, A., Zucker, A., Fong, C. J., Mehine, M. M., Nguyen, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03362-3 · Cited by 119 · see citing works

Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?

Incorvaia, L., Perez, A., Marchetti, C., Brando, C., Gristina, V., Cancelliere, D., Pivetti, A., Contino, S., Giovanni, E. D., Barraco, N., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102650 · Cited by 31 · see citing works

Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma

Huffman, B. M., Ellis, H., Jordan, A. C., Freed-Pastor, W. A., Perez, K. J., Rubinson, D. A., Sethi, N. S., Singh, H., Surana, R., Wolpin, B. M., et al. (2022) · Cancers · doi:10.3390/cancers14246223 · Cited by 30 · see citing works

Pancreatic Cancer: BRCA Targeted Therapy and Beyond

Keane, F., O'Connor, C. A., Park, W., Seufferlein, T. T. W., & O'Reilly, E. M. (2023) · Cancers · doi:10.3390/cancers15112955 · Cited by 25 · see citing works

Management of individuals with heterozygous germline pathogenic variants in ATM: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

Pal, T., Schon, K. R., Astiazarán-Symonds, E., Balmañà, J., Foulkes, W. D., James, P. A., Klugman, S. D., Livinski, A. A., Mak, J. S., Ngeow, J. Y. Y., et al. (2024) · Genetics in Medicine · doi:10.1016/j.gim.2024.101243 · Cited by 21 · see citing works

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

Park, W., O'Connor, C. A., Chou, J. F., Hilmi, M., Tarcan, Z. C., Schwartz, C., Larsen, M., Homsi, R., Sivaprakasam, K., Umeda, S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04299-5 · Cited by 21 · see citing works

The role of molecular testing in pancreatic cancer

Zhen, D. B., Safyan, R. A., Konick, E. Q., Nguyen, R., Pritchard, C. C., & Chiorean, E. G. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231171456 · Cited by 15 · see citing works

Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer

LaRose, M., Manji, G. A., & Bates, S. E. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.11.001 · Cited by 16 · see citing works

Early-onset gastrointestinal cancers: comprehensive review and future directions

Char, S. K., O'Connor, C. A., & Ng, K. (2025) · British journal of surgery · doi:10.1093/bjs/znaf102 · Cited by 13 · see citing works

The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancer

Jiang, B., Shang, Y., Zhang, X., He, W., Hua, H., Ye, F., Zhou, X., Li, Y., Zhong, W., Jiang, W., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf141 · Cited by 11 · see citing works

Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05227-2 · Cited by 10 · see citing works

Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma

Blair, A. B., Radomski, S. N., Chou, J. F., Liu, M., Howell, T. C., Park, W., O'Reilly, E. M., Zheng, L., Balachandran, V. P., Wei, A. C.-C., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16331-4 · Cited by 9 · see citing works

Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan

Kitamura, H., Morizane, C., Tanabe, N., Ikeda, G., Maruki, Y., Ohba, A., Nagashio, Y., Kondo, S., Hijioka, S., Ueno, H., et al. (2023) · Pancreatology · doi:10.1016/j.pan.2023.10.017 · Cited by 8 · see citing works

Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients.

Orsi, G., Carconi, C., Ghiorzo, P., Carrera, P., Pastorino, L., Presi, S., Chiaravalli, M., Barbieri, E., Giordano, G., Sciallero, S., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114226 · Cited by 7 · see citing works

Ataxia telangiectasia mutated (ATM) kinase as a predictive biomarker in clinical oncology: implications for a precision treatment approach

Pham, A. T., Yuan, F., Nagathihalli, N. S., & Dosch, A. R. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101309 · Cited by 5 · see citing works

Defining homologous recombination deficiency status in pancreatic ductal adenocarcinoma: Clinical implications for evaluating response to platinum chemotherapy

Wang, Y., Kong, F.-C., Situ, X., Yang, T., Sun, T., Xie, Z., Pingling, W., Chen, Y., Jiang, N., Dong, Y. J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101291 · Cited by 5 · see citing works

FET fusion oncoproteins disrupt physiologic DNA repair and create a targetable opportunity for ATR inhibitor therapyPreprint

Menon, S., Gracilla, D. E., Breese, M. R., Lin, Y. P., Cruz, F. S. D., Feinberg, T. Y., de Stanchina, E., Galic, A.-F., Allegakoen, H. R., Perati, S. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.30.538578 · Cited by 5 · see citing works

Molecular Characterization and Clinical Relevance of MGMT‐Silenced Pancreatic Cancer

Nichetti, F., Silvestri, M., Agnelli, L., Franza, A., Pircher, C. C., Rota, S., Ambrosini, P., Fotia, G., Hüllein, J., Randon, G., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70393 · Cited by 4 · see citing works

Somatic loss of ATM is a late event in pancreatic tumorigenesis

Paranal, R. M., Jiang, Z., Hutchings, D., Kryklyva, V., Gauthier, C., Fujikura, K., Nanda, N., Huang, B., Skaro, M. F., Wolfgang, C. L., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6136 · Cited by 4 · see citing works

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

Spiekman, I. A. C., Mehra, N., Zeverijn, L. J., Geurts, B. S., Verkerk, K., Mohammad, S. F. H., van der Noort, V., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70191 · Cited by 3 · see citing works

Upper Gastrointestinal Cancers and the Role of Genetic Testing

Harrold, E. C., & Stadler, Z. K. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.01.006 · Cited by 3 · see citing works

Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2

Tsang, E. S., Dhawan, M. S., Pacaud, R., Thomas, S., Grabowsky, J. A., Wilch, L., Karipineni, S., Kelley, R. K., Ko, A. H., Collisson, E. A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00494 · Cited by 3 · see citing works

Results of a multigene panel testing approach targeting patients with suspected genetic predisposition to pancreatic ductal adenocarcinoma

Buecher, B., Warcoin, M., Rolland, E., Abdullazoda, R., Guillevic, A. L., Colas, C., & Golmard, L. (2026) · European Journal of Human Genetics · doi:10.1038/s41431-026-02020-1 · Cited by 2 · see citing works

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancerPreprint

Park, W., Umeda, S., Hilmi, M., O'Connor, C. A., Sharma, R., Tezcan, N., Zhang, H., Zhu, Y., Schwartz, C., Yaqubie, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.15.711961 · Cited by 2 · see citing works

HRD in endometrial cancer: LST loss drives distinct genomic profile and platinum response

Wan, T., Li, Q., Hao, W., Xie, Y., Chen, B., Lin, M., Dai, D., Du, Z., Li, J., & Wei, W. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01347-8 · Cited by 1 · see citing works

Atm Or Chek2 Alterations as Potential Biomarkers of Improved Outcomes with Irinotecan: Real-World Analysis of Advanced Pancreatic Ductal AdenocarcinomaPreprint

Kamgar, M., Mehdi, M., Thapa, B., Szabó, A., Ahmed, G., Shreenivas, A. V., Thomas, J. P., Sriram, D., Evans, D. B., Tsai, S., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4647297 · Cited by 1 · see citing works

Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective

Feng, X., Chai, Y.-H., Jiang, K., Jiang, W., Chen, W.-C., & Pan, Y. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i11.4489

Molecular characterization of hereditary breast and ovarian cancer patients from a public precision medicine service in the Southeast Brazilian population

Ribeiro, A. A. D. F., Ladeira, T. Q., Antunes, M. V. G., Neto, C. P., de Freitas, F. C., de Faria, F. C., Lopes, D. D. O., Tarazona-Santos, E., & dos Santos, L. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-16870-0

Additional file 1 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721084

Additional file 9 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721108

Additional file 13 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721120

Additional file 17 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721132

Additional file 8 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721105

Additional file 11 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721114

Additional file 7 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721102

Additional file 5 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721096

Additional file 12 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721117

Additional file 16 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721129

Additional file 6 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721099

Additional file 10 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721111

Additional file 4 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721093

Additional file 14 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721123

Additional file 2 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721087

Additional file 15 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721126

Additional file 3 of Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort

Vanni, I., Pastorino, L., Andreotti, V., Comandini, D., Fornarini, G., Grassi, M., Puccini, A., Tanda, E. T., Pastorino, A., Martelli, V., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721090

Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitals

García-Díaz, H. C., Gómez-Alonso, J., Rabuñal-Álvarez, M. T., Ochagavía, M., Revuelta-Herrero, J. L., González-Gómez, Á., Riestra, A. C., Noguera, A. O., García, M. M., Farriols, A., et al. (2026) · Journal of Chemotherapy · doi:10.1080/1120009x.2026.2639277

Genomic characterization of ATM alterations in advanced pancreatic ductal adenocarcinoma (PDAC).

Perera, S., Denroche, R. E., Holter, S., Kelly, D., Zhang, A. X. W., Wang, Y., Dodd, A., Ramotar, S., Hutchinson, S., Tehfe, M. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.396 · Cited by 1 · see citing works

Genomic and Immune Landscape of Pancreatic Ductal Adenocarcinoma Associated with Germline Pathogenic Variants in ATM

Yadav, S., Bao, R., Graham, R. P., Hu, C., Hart, S. N., Na, J., Boddicker, N. J., Gnanaolivu, R. D., Smadbeck, J. B., Ding, L., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-4120

Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations

Hannan, Z. M., Yu, S., Domchek, S. M., Mamtani, R., & Reiss, K. A. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa121 · Cited by 20 · see citing works

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection

Park, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M., Balachandran, V. P., McIntyre, C. A., Dika, I. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0418 · Cited by 237 · see citing works

ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications

Armstrong, S. A., Schultz, C. W., Azimi-Sadjadi, A., Brody, J. R., & Pishvaian, M. J. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0208 · Cited by 74 · see citing works